Venus Remedies Limited has informed the Exchange regarding Appointment of Gurminder Singh Bedi as Indepnedent Director of the company w.e.f. May 26, 2026.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies Limited announced appointment of Dr. Gurminder Singh Bedi as Independent Director w.e.f. May 26, 2026, along with re-appointment of other independent directors. The company reported strong FY2026 financials with standalone revenue from operations of Rs. 768.73 crore (up 19% YoY) and consolidated net profit of Rs. 102.78 crore, nearly doubling from Rs. 45.31 crore in FY2025. The board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the 37th AGM scheduled for August 20, 2026. The company also proposed adoption of new MOA and AOA aligned with Companies Act 2013. Multiple independent directors including Mr. Saransh Chaudhary, Dr. Savita Gupta, Mr. Peeyush Jain, and Mr. Ashutosh Jain were also appointed/re-appointed, with some having family relationships to promoters.
Strong financial performance with near-doubling of profits signals operational efficiency; dividend recommendation and board strengthening are positive for shareholders. The promoter family board entries warrant monitoring for governance implications.